NCT00278460View on ClinicalTrials.gov

Gemcitabine and Docetaxel in Treating Patients With Recurrent Stage III or Stage IV Non-Small Cell Lung Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

49

Participants

Timeline

Start Date

November 30, 2000

Primary Completion Date

February 28, 2006

Study Completion Date

September 30, 2007

Conditions
Lung Cancer
Interventions
DRUG

docetaxel

40 milligrams per meter squared infused over 30 minutes on day 1 and 8, repeated every 21 days

DRUG

gemcitabine hydrochloride

800 milligrams per meter squared intraveneously for two consecutive weeks followe by one week of no treatment then repeated.

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Wake Forest University Health Sciences

OTHER

NCT00278460 - Gemcitabine and Docetaxel in Treating Patients With Recurrent Stage III or Stage IV Non-Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter